氨甲环酸对体外休克条件下内皮血管性血友病因子/ADAMTS-13反应的影响
本研究在人脐静脉内皮细胞流动条件下建立仿生休克微流控模型,灌注90分钟后加入氨甲环酸,检测vWF抗原与ADAMTS-13活性并行Western blot分析。结果:休克条件使vWF抗原升高、ADAMTS-13活性降低;氨甲环酸减轻休克诱导的ADAMTS-13-vWF轴裂解,减少血栓性超大vWF。作者据此提出,创伤/失血性休克后早期使用氨甲环酸可能通过保护糖萼、影响vWF-ADAMTS-13轴而减轻微血管灌注异常及后续器官衰竭。氨甲环酸对血小板黏附与聚集的影响尚需进一步研究。
要点
- 体外仿生休克微流控模型:休克条件使vWF抗原升高、ADAMTS-13活性降低。
- 灌注90分钟后加入氨甲环酸,可减轻休克诱导的ADAMTS-13-vWF轴裂解,减少血栓性超大vWF。
- 作者认为这提示创伤/失血性休克后早期给予氨甲环酸或可减轻微血管灌注异常及后续器官衰竭。
- 氨甲环酸对血小板黏附与聚集的影响尚需进一步研究。
- 该结果为体外内皮微流控研究,不能直接推断临床给药时机或剂量。
适用人群与场景
- 人脐静脉内皮细胞在流动条件下建立的体外仿生休克微流控模型,模拟创伤/失血性休克、脓毒症等炎症过程所致内皮激活与糖萼丢失。
诊断标准与关键阈值
- 仿生休克条件由缺氧-复氧与儿茶酚胺过量构成,用于模拟微循环休克状态。
处置流程与药物剂量
- 在灌注90分钟后加入氨甲环酸;原文未给出氨甲环酸的剂量、浓度、给药途径与疗程。
研究设计与关键结果
- 体外内皮微流控流动研究:休克条件使vWF抗原升高、ADAMTS-13活性降低。
- 灌注90分钟后加入氨甲环酸,减轻休克诱导的ADAMTS-13-vWF轴裂解,减少血栓性超大vWF。
- 作者结论:结果提示创伤/失血性休克后早期给予氨甲环酸存在另一机制,或可减轻微血管灌注异常及后续器官衰竭;对血小板黏附与聚集的影响尚需进一步研究。
证据类型、等级与局限
- 证据类型:体外内皮微流控流动实验(人脐静脉内皮细胞)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,创伤/失血性休克后早期给予氨甲环酸可能通过保护糖萼、减少血栓性超大vWF而减轻微血管灌注异常及后续器官衰竭。
- 氨甲环酸对血小板黏附与聚集的影响尚需进一步研究,原文未据此给出临床用药剂量或时机推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Traumatic/hemorrhagic shock, sepsis and other inflammatory processes lead to endothelial activation and a loss of the endothelial glycocalyx. von Willebrand factor (vWF) is an acute phase reactant that is released from endothelial cells and megakaryocytes. Stimulated but not basal vWF leads to significant formation of ultralarge multimers (ultralarge vWF [ULvWF]) and risk for thrombotic complications. Ultralarge vWF is cleaved by a disintegrin and metalloproteinase with a thrombospondin type motif 13 (ADAMTS 13); alterations in ULvWF/ADAMTS 13 ratio may contribute to trauma-induced coagulopathy. Salutary effects of tranexamic acid (TXA) on trauma-induced coagulopathy have been described. These effects appear apart from antifibrinolytic actions of TXA and include protection of the endothelial glycocalyx. Ultralarge vWF is in part anchored to the glycocalyx layer of the endothelium. Tranexamic acid protected the endothelial glycocalyx layer from degradation using a microfluidic model of the microcirculation subjected to hypoxia-reoxygenation and catecholamine excess. We hypothesized that TXA administration following shock conditions would impact the vWF-ADAMTS-13 axis by protecting the glycocalyx from degradation. This was studied in a endothelial microfluidic flow study.
METHODS: Human umbilical vein endothelial cells were established under flow conditions and subjected to biomimetic shock. Tranexamic acid was added after 90 minutes of perfusion. von Willebrand factor antigen and ADAMTS-13 activity were measured. Western blot analysis was performed for vWF characterization from perfusion media.
RESULTS: Shock conditions increased vWF antigen and decreased ADAMTS 13 activity. Tranexamic acid ameliorated shock induced cleavage in the ADAMTS 13-vWF axis with a reduction of the thrombogenic ULvWF.
CONCLUSION: These results suggest another mechanism whereby administration of TXA early following traumatic/hemorrhagic shock mitigates microvascular perfusion abnormalities and subsequent organ failure. The resultant effects on platelet adhesion and aggregation require further study.
参考来源
- Diebel LN, Liberati DM. Effect of tranexamic acid on endothelial von Willebrand factor/ADAMTS-13 response to in vitro shock conditions. J Trauma Acute Care Surg. 2022. PMID: 36322025. doi:10.1097/TA.0000000000003831
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。